
Panelists concurred that precision medicine can serve to exacerbate care inequality if not everyone can access these therapeutics.

Panelists concurred that precision medicine can serve to exacerbate care inequality if not everyone can access these therapeutics.

IL-23 inhibitors linked to lower psoriatic arthritis risk than JAK inhibitors, and IL-17 inhibitors showed higher risk.

FDA approves dexmedetomidine sublingual film for at-home use in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

In the phase 3 ECLIPSE 1 trial, 44% on elebsiran plus tobevibart met the primary end point, with no treatment stops due to serious adverse events.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

A TriNetX retrospective cohort found adults with alopecia areata—especially women—face a nearly doubled glaucoma risk, with implications for ophthalmology and comorbidities.

β3 agonists were not linked to lower dementia incidence vs anticholinergics among 830,393 adults treated for overactive bladder, a cohort study found.

Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.

In 459 patients with FLT3-ITD AML given high-dose anthracycline induction, a high allelic ratio was not linked to survival.

From 9.6 million US diabetic retinopathy cases to a new FDA warning on GLP-1s, here are 5 things to know about diabetic eye disease this November.

New CMS data let EBRI measure what employer plans owe after No Surprises Act arbitration: $8.39B in 2025, though premium impact is unclear.

A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.

Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

One-year open-label MINT data show sustained MG-ADL and QMG score gains with inebilizumab, including in patients who switched from placebo.

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.

Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.

SGLT2 inhibitors were linked to hemoglobin gains of about 1.0 to 1.6 g/dL in small MDS and MPN studies, but a review found no randomized trials to confirm.

Experts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve patient outcomes.

Phase 3 hepatitis delta data, MASH persistence and cost findings, and new PBC treatment targets led The Liver Meeting 2026 in Denver, Colorado.

A prospective Italian study of 492 postmenopausal women found ultrasound signs of deep endometriosis in 7.3%, often plaque-like and poorly vascularized.

AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.

In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.

First-line IVF produced more live births than IUI within 7 months in couples with unexplained infertility.

Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.

The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.

Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days.